Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Capital Expenditures for 6 consecutive years, with -$83000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 143.23% to -$83000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $975000.0, a 141.94% increase, with the full-year FY2024 number at $568000.0, up 1036.0% from a year prior.
  • Capital Expenditures was -$83000.0 for Q3 2025 at Vivos Therapeutics, down from $771000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.3 million in Q2 2021 to a low of -$1.9 million in Q4 2021.
  • A 5-year average of $136777.8 and a median of $178500.0 in 2024 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 16701.23% in 2021; the steepest drop was 2104.44% in 2021.
  • Vivos Therapeutics' Capital Expenditures stood at -$1.9 million in 2021, then surged by 110.5% to $200000.0 in 2022, then tumbled by 317.0% to -$434000.0 in 2023, then surged by 138.02% to $165000.0 in 2024, then tumbled by 150.3% to -$83000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Capital Expenditures are -$83000.0 (Q3 2025), $771000.0 (Q2 2025), and $122000.0 (Q1 2025).